Detalles de la búsqueda
1.
Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design.
Mov Disord
; 38(10): 1774-1785, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37363815
2.
Re-Analysis of the STEADY-PD II Trial-Evidence for Slowing the Progression of Parkinson's Disease.
Mov Disord
; 37(2): 334-342, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34766657
3.
Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy.
J Infect Dis
; 222(4): 601-610, 2020 07 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-32201883
4.
Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s.
Br J Clin Pharmacol
; 86(1): 132-142, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31656054
5.
Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.
Antimicrob Agents Chemother
; 63(4)2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30642925
6.
Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques.
Antimicrob Agents Chemother
; 61(5)2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28264852
7.
Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s.
J Antimicrob Chemother
; 72(7): 2042-2048, 2017 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28369419
8.
Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.
Ther Drug Monit
; 39(6): 596-603, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29135907
9.
Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation.
Liver Transpl
; 22(3): 287-97, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26437376
10.
A review of disease progression models of Parkinson's disease and applications in clinical trials.
Mov Disord
; 31(7): 947-956, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27226141
11.
Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.
Clin Infect Dis
; 58(4): 555-63, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24253247
12.
Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.
J Antimicrob Chemother
; 69(12): 3300-10, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25159623
13.
Developing better digital health measures of Parkinson's disease using free living data and a crowdsourced data analysis challenge.
PLOS Digit Health
; 2(3): e0000208, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36976789
14.
Pharmacologic approaches to the treatment of Huntington's disease.
Mov Disord
; 27(1): 31-41, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21997232
15.
Prevalence and Incidence of Nonmotor Symptoms in Individuals with and Without Parkinson's Disease.
Mov Disord Clin Pract
; 9(7): 961-966, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36247906
16.
Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.
Ther Drug Monit
; 33(3): 309-14, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21544014
17.
Isradipine plasma pharmacokinetics and exposure-response in early Parkinson's disease.
Ann Clin Transl Neurol
; 8(3): 603-612, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33460320
18.
A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation.
Clin Pharmacol Ther
; 110(2): 508-518, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33894056
19.
Pharmacotherapy Use for Non-Motor Symptoms Among de novo Parkinson's Disease Parkinson's Progression Markers Initiative Participants.
J Parkinsons Dis
; 10(3): 1239-1243, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32417797
20.
Toward precision prescribing for methadone: Determinants of methadone deposition.
PLoS One
; 15(4): e0231467, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32302325